Overview
Most metabolic-research compounds in this catalog are incretin-system agonists (GLP-1, GIP, and glucagon-receptor ligands) and related signaling molecules. The published literature studies them for metabolic and body-composition research endpoints. This guide describes how the compound is characterized and what that research covers. It is not usage guidance and makes no claim about outcomes from use.
A novel long-acting metabolic research candidate. Published literature is minimal; included for exploratory research.
Evidence at a glance: No efficacy evidence cited
No published efficacy evidence is cited for this compound. We state that plainly rather than pad the page.
Molecular identity
- Molecular formula
- Not published
- Molecular weight
- ~4,900 g/mol (estimated)
- CAS number
- Not assigned (novel)
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 98.5%
Researched mechanism
Reported as a long-acting incretin-class agonist; mechanism details are not yet published.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
Evidence
Honest note on evidence: No peer-reviewed literature is currently available on this compound. It is offered strictly as a novel research material; no efficacy, mechanism, or safety is claimed.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| Retatrutide | Status | Retatrutide is well-characterized; LC865 is exploratory. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 10 mg | 2 mL | 5 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Common questions
Why is there no evidence section?+
Because none is published. We state that plainly rather than pad the page, honest thinness is the policy.
